Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of ...

The agreements cap monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs for ...

Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's Ozempic may modestly reduce the risk of obesity-related ...

Wegovy belongs to a pricey class of drugs called GLP-1s (short for glucagon-like peptide-1 agonists) that have upended the ...

The Danish drugmaker unveiled a series of initiatives to increase access to Wegovy and clamp down on use of the knock-off ...

Health plan sponsors are also expected to see a reduction in the net cost per prescription of GLP-1 medications to treat obesity.

Novo Nordisk reduced its starter dose prices through telehealth platforms to encourage patients to wean themselves off compounded copycats.

Cigna has announced a deal to cap client copays on popular GLP-1 weight loss drugs by Eli Lilly and Novo Nordisk at $200 per ...

Newly recognized issues, including extreme fatigue with excessive weight reduction, bone loss, and abdominal pain, point to ...

Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, T2D and other metabolic diseases.

The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to ...